Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apraglutide PK and Safety in Renal Impairment
NCT04699032Phase 1Completed
- Sponsor
- VectivBio
- Start
- Dec 2020
- Primary completion
- Jul 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of apraglutide in short bowel syndrome (SBS) (4 arms), sponsored by VectivBio. Primary endpoints: Maximum Plasma Concentration of Apraglutide and Area Under the Concentration-time Curve From Time Zero to Infinity. Started Dec 2020; status: completed.
02
Drugs
apraglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT04699032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04699032.